Enhanced Influenza Vaccination for Elderly Populations

The present inventive concept relates to novel vaccine compositions and methods for enhancing immunogenicity and safety of influenza vaccines in elderly populations, addressing the limitations of existing vaccines.

The original patent disclosed a method for boosting immunogenicity of vaccines using saponins and agonists of the intracellular stimulator of interferon genes pathway. However, the existing approach has limitations in terms of efficacy and safety in elderly populations. The present inventive concept addresses these limitations by optimizing saponin mixtures, incorporating agonists of the intracellular stimulator of interferon genes pathway, and introducing tolerogenic agents to enhance safety.

The new vaccine composition comprises an influenza antigen and an optimized saponin mixture tailored to elderly populations, which enhances immunogenicity. The method involves administering an effective amount of the influenza vaccine in combination with the saponin mixture and an agonist of the intracellular stimulator of interferon genes pathway. Additionally, the inventive concept includes a system for personalized influenza vaccination, where the saponin mixture is tailored to an individual's immune profile, and a kit for preparing an influenza vaccine with instructions for administration to elderly populations. The inventive concept also includes a method for enhancing the safety of influenza vaccines in elderly populations by administering the vaccine with a tolerogenic agent.

The novelty of the present inventive concept lies in the optimization of saponin mixtures, the incorporation of agonists of the intracellular stimulator of interferon genes pathway, and the introduction of tolerogenic agents to enhance safety. The inventive step is the combination of these elements to create a more effective and safer vaccine for elderly populations.

Alternative embodiments of the inventive concept include using different types of saponins, varying the ratio of saponins to influenza antigen, and incorporating additional immunostimulants. Variations of the inventive concept include using the optimized saponin mixture with different types of vaccines, such as HIV or cancer vaccines, and developing a system for personalized vaccination for other age groups or populations.

The present inventive concept has significant commercial potential in the vaccine industry, particularly in the elderly population segment. The enhanced immunogenicity and safety of the vaccine composition and method make it an attractive solution for pharmaceutical companies, healthcare providers, and governments seeking to improve public health.